Huls G, Chitu DA, Tick L, Boersma R, et al. Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. Ann Hematol 2025;104:361-368.
PMID: 39367118